Last reviewed · How we verify
Bloxiverz (NEOSTIGMINE)
Bloxiverz works by blocking the enzyme acetylcholinesterase, allowing more acetylcholine to be available in the nervous system.
Bloxiverz (NEOSTIGMINE) is a small molecule cholinesterase inhibitor developed by ECLAT PHARMS LLC and currently owned by Fresenius Kabi Usa. It targets acetylcholinesterase to increase acetylcholine levels in the nervous system. Bloxiverz is FDA-approved for treating Myasthenia gravis, retention of urine, and reversal of neuromuscular blockade. The drug is off-patent with 16 generic manufacturers available. Key safety considerations include its short half-life of 1.3 hours and low bioavailability of 2%.
At a glance
| Generic name | NEOSTIGMINE |
|---|---|
| Sponsor | Fresenius Kabi |
| Drug class | Cholinesterase Inhibitor |
| Target | Acetylcholinesterase |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
| First approval | 2013 |
Mechanism of action
. Mechanism of Action. Neostigmine methylsulfate is competitive cholinesterase inhibitor. By reducing the breakdown of acetylcholine, neostigmine methylsulfate induces an increase in acetylcholine in the synaptic cleft which competes for the same binding site as nondepolarizing neuromuscular blocking agents, and reverses the neuromuscular blockade.
Approved indications
- Myasthenia gravis
- Retention of urine
- Reversal of neuromuscular blockade
Common side effects
- bradycardia
- nausea
- vomiting
Key clinical trials
- Impact of Sugammadex Versus Neostigmine on Early Postoperative Pulmonary Function (NA)
- Neostigmine and Glycopyrrolate for the Treatment of Headache After Dural Puncture (PHASE2)
- Risk of Acute Complications With Rocuronium vs Cisatracurium in Patients With Chronic Kidney Disease (PHASE4)
- Neostigmine as an Adjuvant in Tranversus Abdominis Plane (TAP) Block in Cesarean Section Under Spinal Anesthesia (NA)
- A Comparative Study Between Combination of Propofol and Dexmedetomidine Versus Propofol Alone in Anesthesia for Rigid Bronchoscopy by Using the Patient State Index Monitor (PHASE4)
- NMBA Reversal and Postoperative Urinary Retention
- Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection (PHASE4)
- Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bloxiverz CI brief — competitive landscape report
- Bloxiverz updates RSS · CI watch RSS
- Fresenius Kabi portfolio CI